This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Jazz Pharma (JAZZ) Q3 Earnings Beat, New Drugs Drive Sales
by Zacks Equity Research
Jazz Pharma's (JAZZ) product revenues grow in the third quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.
Jazz Pharmaceuticals (JAZZ) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 28.44% and 0.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline
by Zacks Equity Research
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Axsome (AXSM) Begins Late-Stage Sleep Disorder Study on AXS-12
by Zacks Equity Research
Axsome (AXSM) is developing AXS-12 as a potential treatment for narcolepsy. The company initiates enrollment in a phase III study evaluating AXS-12.
Jazz (JAZZ) Down 14.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bio-Path (BPTH) to Begin Clinical Study on Leukemia Drug
by Zacks Equity Research
Bio-Path Holdings' (BPTH) IND application for BP1002 receives clearance from the FDA. It is set to begin a phase I/Ib study for treating AML patients. The stock rises following the announcement.
Pharma Stock Roundup: FDA Nod for SNY's Pompe Drug & New Use of MRK's Keytruda
by Kinjel Shah
FDA approves Sanofi's (SNY) Nexviazyme for late-onset Pompe disease and Merck's (MRK) Keytruda plus Lenvima for first-line kidney cancer.
Jazz's (JAZZ) Xywav Gets FDA Nod for Idiopathic Hypersomnia
by Zacks Equity Research
Jazz's (JAZZ) Xywav gets FDA approval for new indication, idiopathic hypersomnia. Following approval, Xywav becomes the first drug for treatment of this sleep disorder.
Jazz's (JAZZ) Epidyolex Gets Approval for New Indication in UK
by Zacks Equity Research
Jazz's (JAZZ) unit GW Pharmaceuticals' Epidyolex (cannabidiol) gets a regulatory nod for a new indication in the United Kingdom. Following this announcement, stock prices fell.
Jazz Pharma (JAZZ) Q2 Earnings Beat, Sales Ride on GW Buyout
by Zacks Equity Research
Jazz Pharma's (JAZZ) product revenues grow in the second quarter on the back of strong demand for its new drugs and additional sales from drugs added with the acquisition of GW Pharmaceuticals.
Jazz Pharmaceuticals (JAZZ) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 9.86% and 1.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
How Investors Can Grab Better Returns for Medical Using the Zacks ESP Screener
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Jazz Pharmaceuticals (JAZZ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 16th
by Zacks Equity Research
JAZZ, MRNS, TWO, NCMI, and CRON have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2021
Axsome (AXSM) Falls 10% After Losing Breakthrough Therapy Tag
by Zacks Equity Research
The FDA rescinds Breakthrough Therapy designation for Axsome's (AXSM) pipeline candidate, AXS-12. The company is developing AXS-12 for the potential treatment of cataplexy in narcolepsy patients.
Jazz Pharma (JAZZ) Gets FDA Approval for Leukemia Drug Rylaze
by Zacks Equity Research
Jazz Pharma (JAZZ) gets FDA approval for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.
New Strong Sell Stocks for June 22nd
by Zacks Equity Research
ABT, BNL, ITRG, JAZZ, and MANU have been added to the Zacks Rank #5 (Strong Sell) List on June 22, 2021
Why Is Jazz (JAZZ) Up 1.8% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Strength Seen in Jazz (JAZZ): Can Its 6.6% Jump Turn into More Strength?
by Zacks Equity Research
Jazz (JAZZ) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Jazz Pharma (JAZZ) Q1 Earnings Beat, Sales Miss, Stock Down
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports mixed first-quarter 2021 results as earnings beat estimates while sales miss the same. Shares down
Jazz Pharmaceuticals (JAZZ) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 6.23% and 0.16%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Alzheimer's Disease: 5 Stocks on Biotech Radars
by Kevin Cook
While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.